Latest News
GSK hepatitis B therapy bepirovirsen gains FDA priority review and breakthrough designation
28 April 2026 - Biopharmaceutical company GSK plc (LON:GSK) (NYSE:GSK) announced on Tuesday that the US Food and Drug Administration (FDA) has accepted its New Drug Application for bepirovirsen for priority review in adults with chronic hepatitis B.T...
Boehringer Ingelheim's survodutide phase 3 data show significant weight loss in obesity trial
28 April 2026 - Danish biotechnology company Zealand Pharma A/S (CPH:ZEAL) reported on Tuesday that pharmaceutical company Boehringer Ingelheim has achieved positive Phase 3 results for survodutide, a glucagon/GLP-1 dual agonist, in the SYNCHRONIZE-1...
Johnson & Johnson IMAAVY (nipocalimab-aahu) granted FDA Priority Review as potential treatment for wAIHA
28 April 2026 - US healthcare company Johnson & Johnson (J&J) (NYSE:JNJ) announced on Monday that the US Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics License Application (sBLA) for IMAAVY (nipoc...
Xcovery and EVERSANA partner for US commmercialisation of lung cancer drug Ensacove
28 April 2026 - US pharmaceutical company Xcovery Holdings Inc announced on Monday an agreement with EVERSANA, a provider of commercialisation services to the global life sciences industry, to support and expand the US commercial launch of Ensacove (...
Jazz Pharmaceuticals reports FDA acceptance and Priority Review of sBLA for Ziihera (zanidatamab-hrii) combinations in first-line HER2+ locally advanced or metastatic GEA
28 April 2026 - US pharmaceutical company Jazz Pharmaceuticals plc (Nasdaq:JAZZ) announced on Monday that the US Food and Drug Administration (FDA) has accepted for filing with Priority Review the supplemental Biologics License Application (sBLA) for...